Abstract:EEG plays an integral part in the diagnosis and management of children with genetic epilepsies. Nevertheless, how quantitative EEG features differ between genetic epilepsies and neurological outcomes remains largely unknown. Here, we aimed to identify quantitative EEG biomarkers in children with epilepsy and a genetic diagnosis in STXBP1, SCN1A, or SYNGAP1, and to assess how quantitative EEG features associate with neurological outcomes in genetic epilepsies more broadly. We analyzed individuals with pathogenic variants in STXBP1 (95 EEGs, n=20), SCN1A (154 EEGs, n=68), and SYNGAP1 (46 EEGs, n=21) and a control cohort of individuals without epilepsy or known cerebral disease (847 EEGs, n=806). After removing artifacts and epochs with excess noise or altered state from EEGs, we extracted spectral features. We validated our preprocessing pipeline by comparing automatically-detected posterior dominant rhythm (PDR) to annotations from clinical EEG reports. Next, as a coarse measure of pathological slowing, we compared the alpha-delta bandpower ratio between controls and the different genetic epilepsies. We then trained random forest models to predict a diagnosis of STXBP1, SCN1A, and SYNGAP1. Finally, to understand how EEG features vary with neurological outcomes, we trained random forest models to predict seizure frequency and motor function. There was strong agreement between the automatically-calculated PDR and clinical EEG reports (R2=0.75). Individuals with STXBP1-related epilepsy have a significantly lower alpha-delta ratio than controls (P<0.001) across all age groups. Additionally, individuals with a missense variant in STXBP1 have a significantly lower alpha-delta ratio than those with a protein-truncating variant in toddlers (P<0.001), children (P=0.02), and adults (P<0.001). Models accurately predicted a diagnosis of STXBP1 (AUC=0.91), SYNGAP1 (AUC=0.82), and SCN1A (AUC=0.86) against controls and from each other in a three-class model (accuracy=0.74). From these models, we isolated highly correlated biomarkers for these respective genetic disorders, including alpha-theta ratio in frontal, occipital, and parietal electrodes with STXBP1, SYNGAP1, and SCN1A, respectively. Models were unable to predict seizure frequency (AUC=0.53). Random forest models predicted motor scores significantly better than age-based null models (P<0.001), suggesting spectral features contain information pertinent to gross motor function. In summary, we demonstrate that STXBP1-, SYNGAP1-, and SCN1A-related epilepsies have distinct quantitative EEG signatures. Furthermore, EEG spectral features are predictive of some functional outcome measures in patients with genetic epilepsies. Large-scale retrospective quantitative analysis of clinical EEG has the potential to discover novel biomarkers and to quantify and track individuals' disease progression across development.

Quantitative EEG biomarkers for STXBP1‐related disorders

Quantitative EEG Spectral Features Differentiate Genetic Epilepsies and Predict Neurologic Outcomes

Epilepsy Course and Developmental Trajectories in STXBP1-DEE

Delineating clinical and developmental outcomes in STXBP1-related disorders

Genotype and phenotype spectrum of 10 children with STXBP1 gene-related encephalopathy and epilepsy

Assessing the Landscape of STXBP1-related Disorders in 534 Individuals

Bibliometric Analysis of Quantitative Electroencephalogram Research in Neuropsychiatric Disorders From 2000 to 2021

Excitation/Inhibition balance relates to cognitive function and gene expression in temporal lobe epilepsy: a high density EEG assessment with aperiodic exponent

Unveiling the disease progression in developmental and epileptic encephalopathies: Insights from EEG and neuropsychology

Developmental outcome of electroencephalographic findings in SYNGAP1 encephalopathy

Excitation/Inhibition balance relates to cognitive function and gene expression in Temporal Lobe Epilepsy: an hdEEG assessment with aperiodic exponent

Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy

Clinical Analysis of Developmental And/or Epileptic Encephalopathy with Spike-and-wave Activation in Sleep: a Single Tertiary Care Center Experience in China

Clinical spectrum of STX1B-related epileptic disorders

P235 Localizing non-epileptic abnormal brain function in children using high density EEG (HDEEG): Electric source imaging (ESI) of focal slowing

PPP3CA gene-related developmental and epileptic encephalopathy: Expanding the electro-clinical phenotype

Early mortality in STXBP1-related disorders

Quality of life, socioeconomic and psychological concerns in parents of children with tuberous sclerosis complex, STXBP1 and SYNGAP1 encephalopathies: a mixed method study

A De Novo Splicing Mutation of STXBP1 in Epileptic Encephalopathy Associated with Hypomyelinating Leukodystrophy

Early life seizures and epileptic spasms in STXBP1‐related disorders

Quantitative analysis of visually normal EEG reveals spectral power abnormalities in temporal lobe epilepsy